Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GLPG
- Price
- 27.42
- Stock movement up
- +0.16 (0.50%)
- Company name
- Galapagos NV ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.10B
- Ent value
- 3.36B
- Price/Sales
- -
- Price/Book
- 0.73
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 10.19
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 28.40%
- 3 year return
- -16.39%
- 5 year return
- -30.26%
- 10 year return
- -6.09%
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GLPG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 10.19 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 111.66 |
| EV to EBITDA | 178.23 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.73 |
| EV to Sales | -374.31 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.90M |
| EPS (TTM) | 3.13 |
| FCF per share (TTM) | -6.11 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -8.97M |
| Gross profit (TTM) | -112.52M |
| Operating income (TTM) | -211.56M |
| Net income (TTM) | 206.33M |
| EPS (TTM) | 3.13 |
| EPS (1y forward) | -0.97 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 1254.40% |
| Operating margin (TTM) | 2358.57% |
| Profit margin (TTM) | -2300.27% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 55.52M |
| Net receivables | 87.23M |
| Total current assets | 3.56B |
| Goodwill | 69.47M |
| Intangible assets | 173.43M |
| Property, plant and equipment | 0.00 |
| Total assets | 4.17B |
| Accounts payable | 115.86M |
| Short/Current long term debt | 11.46M |
| Total current liabilities | 351.23M |
| Total liabilities | 1.31B |
| Shareholder's equity | 2.86B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -317.96M |
| Capital expenditures (TTM) | 84.39M |
| Free cash flow (TTM) | -402.35M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 7.21% |
| Return on Assets | 4.95% |
| Return on Invested Capital | 7.20% |
| Cash Return on Invested Capital | -14.03% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 31.67 |
| Daily high | 32.00 |
| Daily low | 31.39 |
| Daily Volume | 208K |
| All-time high | 274.03 |
| 1y analyst estimate | 25.43 |
| Beta | -0.05 |
| EPS (TTM) | 3.13 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Nov 2025 |
Downside potential
Loading...
Downside potential data
| GLPG | S&P500 | |
| Current price drop from All-time high | -88.35% | -1.46% |
| Highest price drop | -91.72% | -56.47% |
| Date of highest drop | 4 Feb 2025 | 9 Mar 2009 |
| Avg drop from high | -39.52% | -10.99% |
| Avg time to new high | 23 days | 12 days |
| Max time to new high | 1382 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.10B
Marketcap category
Mid-cap
Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Employees
558
Website
Investor relations
-
SEC filings
CEO
Onno van de Stolpe
Country
USA
City
Mechelen
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page